Promising work, especially in light of FDA-approved AAV gene therapy entering the U.S. market early this year to restore vision in patients diagnosed with biallelic RPE65-mutation-associated ret...
We and selected partners, use cookies or similar technologies as specified in the cookie policy.
You can consent to the use of such technologies by closing this notice.
Cookie Control
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activites described below. To learn more about how these trackers help us
and how they work, refer to the cookie policy. You may review and change your preferences at any time.
These trackers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.
These trackers help us to provide a personalized user experience by improving the quality of your preference management options, and by enabling the interaction with external networks and platforms.
If you are a registered user on Nature Portfolio Cancer Community, please sign in.
Sign in to Nature Portfolio Cancer Community
Nature Portfolio Cancer Community is for all those interested in cancer research, including our journal readers and authors, educators, and those working in medicine, industry and healthcare
Recent Comments
Promising work, especially in light of FDA-approved AAV gene therapy entering the U.S. market early this year to restore vision in patients diagnosed with biallelic RPE65-mutation-associated ret...